Category Archives: Cell Medicine

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT, OTCBB: ACTC), a leader in the field of regenerative medicine, today announced year-end results for the year ended December 31, 2011. The Company utilized $13.6 million in cash for operations during the year, compared to $8.8 million in the year-earlier period. The increase in cash utilization resulted primarily from ACTs ongoing clinical activities in the US and Europe. ACT ended the year with cash and cash equivalents of $13.1 million, compared to $15.9 million in cash and cash equivalents in the year-earlier period. Some of the 2011 highlights included: 2011 was a very important and successful year for ACT as we began our Phase 1/2 trials for the treatment of macular degeneration, said Gary Rabin, chairman and CEO of ACT. We are very excited about the preliminary Phase 1/2 clinical data from our dry-AMD and Stargardts disease trials, which were published in The Lancet earlier this year. The data demonstrated the safety of ACTs human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells for the treatment of both diseases. The vision of both patients appears to have improved after transplantation, and no adverse safety issues have been observed. We look forward … Continue reading →

28-02-2012 16:31 Learn more about cord blood stem cells here http://www.cordblood.com Cord Blood Registry takes pride in leading the cord blood banking industry with its state-of-the-art lab. Meet Kristen, who leads the effort to make sure we're providing our clients with the best once their babies' stem cells arrive in Tucson. Kristen is one of the many people who make sure that, from that first phone call to the day your baby's stem cells are collected and stored, you receive the industry's best service and support. For more information on CBR's processes, visit: http://www.cordblood.com Read the rest here: Meet Cord Blood Registry's Leader of Laboratory Operations - Video … Continue reading →

28-02-2012 16:31 Learn more about cord blood stem cells here http://www.cordblood.com Cord Blood Registry takes pride in leading the cord blood banking industry with its state-of-the-art lab. Meet Kristen, who leads the effort to make sure we're providing our clients with the best once their babies' stem cells arrive in Tucson. Kristen is one of the many people who make sure that, from that first phone call to the day your baby's stem cells are collected and stored, you receive the industry's best service and support. For more information on CBR's processes, visit: http://www.cordblood.com Read the rest here: Meet Cord Blood Registry's Leader of Laboratory Operations - Video … Continue reading →

29-02-2012 12:13 Low-Level Laser Therapy is a completely safe, noninvasive, nonthermal therapy in which a special type of light penetrates the surface of the skin and underlying tissues to stimulate natural healing in the body. The body's cells are exposed to photon energy, which in turn: Reduces pain Reduces inflammation Increases circulation Increases cellular ATP production Releases tight muscles (both smooth and striated) Speeds bone repair FDA Approves Low-Level Laser for Osteoarthritis Billions of dollars equal a staggering loss in the United States economy due to medical costs and decrease in productivity. The culprit, osteoarthritis. However, the United States Food and Drug Administration (FDA) cleared a new therapy that alleviates pain and inflammation with no side effects. This marks the first low-level laser to be cleared by the FDA for treating osteoarthritis of the hand. This therapy is the Q-Laser System, a low-level laser, now available in our clinics in San Diego and Oceanside. Osteoarthritis cannot currently be cured, but effective treatments can improve the quality of life of millions of people. To many people, it comes as exciting news that the FDA has recently approved a low-level laser treatment, the Q-1000 Laser, for treating osteoarthritis in the hands. The … Continue reading →

29-02-2012 12:13 Low-Level Laser Therapy is a completely safe, noninvasive, nonthermal therapy in which a special type of light penetrates the surface of the skin and underlying tissues to stimulate natural healing in the body. The body's cells are exposed to photon energy, which in turn: Reduces pain Reduces inflammation Increases circulation Increases cellular ATP production Releases tight muscles (both smooth and striated) Speeds bone repair FDA Approves Low-Level Laser for Osteoarthritis Billions of dollars equal a staggering loss in the United States economy due to medical costs and decrease in productivity. The culprit, osteoarthritis. However, the United States Food and Drug Administration (FDA) cleared a new therapy that alleviates pain and inflammation with no side effects. This marks the first low-level laser to be cleared by the FDA for treating osteoarthritis of the hand. This therapy is the Q-Laser System, a low-level laser, now available in our clinics in San Diego and Oceanside. Osteoarthritis cannot currently be cured, but effective treatments can improve the quality of life of millions of people. To many people, it comes as exciting news that the FDA has recently approved a low-level laser treatment, the Q-1000 Laser, for treating osteoarthritis in the hands. The … Continue reading →

LONDON (Reuters) - Britain's Nuffield Council on Bioethics, which examines ethical issues raised by new developments in biology and medicine, launched a consultation on Thursday on the ethics of new technologies and devices that intervene in the human brain. The three main areas of the group's focus are brain-computer interfaces, neurostimulation and neural stem cell therapy. Here are some details about each area of research and how it is being explored. * Brain computer interfaces (BCIs) BCIs measure and analyze a person's brain signals and convert them into an output such as movement. A paralyzed person, for example, could use a BCI to operate a wheelchair, or someone who has extreme difficulty speaking could use a BCI to communicate via a computer voice. These sorts of applications have been shown to be successful in a few reported cases, but the technology has not yet been developed for regular clinical use and there are questions over whether these technologies are reliable enough for use in everyday life. Military applications, such as remote control of vehicles and machinery are not yet in wide use but are being researched and tested, mainly in the United States. Some commercial BCI developments are already on … Continue reading →

MOUNTAIN VIEW, Calif., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Complete Genomics Inc. (Nasdaq:GNOM - News), the whole human genome sequencing company, today announced the formation of its Genomic Medicine Advisory Board (GMAB). The GMAB will provide insight and guidance on the best ways for the company to provide sequencing services to healthcare organizations and physicians interested in implementing genomic medicine in their practice. Inaugural board members include distinguished physicians and scientists. Robert Nussbaum, MD, Holly Smith Professor of Medicine, chief of the Division of Medical Genetics in the Department of Medicine, and director of the Cancer Risk and Cardiovascular Genetics Programs at the University of California, San Francisco, will serve as GMAB chairman. "There are a number of major challenges to deploying whole genome sequencing in the clinic," said Dr. Nussbaum. "The Complete Genomics GMAB is a wonderful opportunity to assemble thought leaders in genomic medicine to begin to define the 'clinical genome' and how to make it most useful and accessible to clinicians, establish technical and ethical standards, and address some of the regulatory and reimbursement obstacles that exist in this rapidly-evolving field. Complete Genomics is committed to doing this right." Founding members of the Complete Genomics GMAB include … Continue reading →

Regenerative Medicine Institute, Mexico has been granted full accreditation for its clinical stem cell trials Portland, Oregon (PRWEB) February 29, 2012 We are pleased that RMI undertook this process, says David Audley, executive director of the ICMS. The clinic understood that patient safety can only be assured through strict evaluation and rigorous oversight. From day one they have embraced the transparency that this program requires. RMI is the first clinic to achieve this status under the ICMS Accreditation Program. The clinic has undergone two separate site audits as well as an institutional review board review evaluation. Most importantly, the clinic has placed in excess of 50 patients into the Treatment Registry for long-term outcome tracking. The safety profile has been excellent, continued Audley. We have tracked patients over at least two follow-ups and a minimum of six months and not seen a single cell-related adverse event. The ICMS is currently evaluating nearly a dozen clinics worldwide. Accreditation is based upon the Guidelines for the Practice of Cell-Based Medicine developed and published by the ICMS. Key components of these guidelines are the ethical recruitment of patients, proper consent of patients and compliance with local laws and regulations in the treatment of … Continue reading →

Women may make new eggs throughout their reproductive yearschallenging a longstanding tenet that females are born with finite supplies, a new study says. The discovery may also lead to new avenues for improving women's health and fertility. A woman has two ovaries, which release eggs during her monthly ovulation.(Learn more about the human body.) Previous research had suggested that a woman is born with all the egg cells she will ever have in her lifetime. But in recent experiments, scientists discovered a new type of stem cell in the ovaries thatwhen grown in the labgenerates immature egg cells.The same immature cells isolated from adult mouse ovaries canturn into fertile eggs. Stem cells,found in embryos and certain adult body tissues, have the potential to grow into many different types of cells. (See"Liposuction Fat Turned Into Stem Cells, Study Says.") The finding reinforces the team's previous experiments in mice, which had identified a new type of ovarian stem cell that renews a female mouse's source of eggs throughout its fertile years. That study, published in the journal Nature in 2004, was the "first to reach the conclusion that this long-held belief in our fieldthat young girls are given a bank account at … Continue reading →

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will release 2011 fourth quarter and year-end results on Thursday, March 1st after the market closes. The Company will hold a conference call on Friday, March 2nd at 9:00 am eastern time to discuss the results and provide an update on clinical activities. Interested parties should dial (888)264-3177 followed by the reference conference ID number 57426004. The call will be available live and for replay by webcast at: http://us.meeting-stream.com/advancedcelltechnology030212 About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar … Continue reading →